Methocarbamol
Robaxin, Robaxin-750
Methocarbamol Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Discomfort associated with acute, painful musculoskeletal conditions | Adults and adolescents ≥16 years (oral); adults (injectable) | Adjunct to rest, physical therapy, and other measures | FDA Approved |
| Tetanus — control of neuromuscular manifestations (injectable only) | Adults and pediatric patients | Adjunct to standard tetanus management (debridement, antitoxin, antibiotics, supportive care) | FDA Approved |
Methocarbamol has been FDA-approved for muscle spasms since 1957, making it one of the oldest muscle relaxants in clinical use. It is a carbamate derivative of guaifenesin that acts through general central nervous system depression rather than directly on skeletal muscle. Despite more than 3 million prescriptions annually in the United States, limited high-quality clinical trial data is available. A 2018 randomized controlled trial by Friedman et al. found that adding methocarbamol to naproxen did not improve outcomes at one week for acute low back pain. However, methocarbamol demonstrates consistently lower injury rates compared to other muscle relaxants when combined with opioids, and it appears to be less sedating than cyclobenzaprine.
Muscle spasm associated with rib fractures — Several trials suggest methocarbamol may improve recovery and decrease hospital length of stay. Used as part of multimodal analgesia. Evidence quality: Low to Moderate.
Rheumatoid arthritis-associated muscle spasm — Some suggestion of symptom improvement, but insufficient evidence regarding optimal dosing and functional outcomes. Evidence quality: Very Low.
Methocarbamol Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute musculoskeletal spasm — initial loading (oral) | 1500 mg QID | 1000 mg QID or 1500 mg TID | 8 g/day (severe); 6 g/day (typical) | 6 g/day for first 48–72 h, then reduce to ~4 g/day Use 3 x 500 mg tablets QID or 2 x 750 mg tablets QID for loading |
| Acute musculoskeletal spasm — maintenance (oral) | 750–1000 mg QID | 4–4.5 g/day in 3–6 divided doses | 6 g/day | Step down after initial 48–72 h loading 750 mg q4h or 1500 mg TID are common maintenance schedules |
| Severe musculoskeletal spasm or oral not feasible — parenteral | 1 g IV or IM | 1 g q8h IV/IM | 3 g/day for max 3 consecutive days | IV rate must not exceed 3 mL/min (300 mg/min) IM: max 500 mg (5 mL) per gluteal site; switch to oral as soon as feasible |
| Tetanus — adults (injectable) | 1–2 g IV initially | 1–2 g IV q6h; then up to 24 g/day via NG tube | Up to 3 g IV per dose; up to 24 g/day orally via NG | Repeat IV q6h until NG tube placed; crushed tablets in water/saline via NG Adjunct only; does not replace antitoxin, antibiotics, or supportive care |
| Tetanus — pediatric (injectable only) | 15 mg/kg IV or 500 mg/m² | 15 mg/kg IV q6h as needed | 1.8 g/m²/day for max 3 consecutive days | Only FDA-approved pediatric use is for tetanus Oral formulation not established for safety/efficacy in patients <16 years |
| Elderly patients | 500–750 mg TID | Lowest effective dose | 4 g/day | Start low; AGS Beers Criteria lists skeletal muscle relaxants as potentially inappropriate in older adults Half-life slightly prolonged (1.5 h vs 1.1 h); increased fall and sedation risk |
Methocarbamol uses a higher initial dose for the first 48–72 hours (6 g/day, or up to 8 g/day for severe conditions), then steps down to approximately 4–4.5 g/day for maintenance. This front-loading approach provides faster relief during the acute phase while minimizing cumulative CNS-depressant exposure. In clinical practice, many patients receive lower doses than the PI recommends — a retrospective cohort study found the typical inpatient dose was 500 mg every 8 hours. Always reassess the need for continued therapy after the initial treatment period.
Pharmacology
Mechanism of Action
The precise mechanism of methocarbamol in humans has not been fully established. Its muscle-relaxant effect is thought to arise from general central nervous system depression rather than any direct action on the contractile machinery of skeletal muscle, the motor end plate, or the nerve fibre. Pharmacological studies suggest that methocarbamol may act by blocking spinal polysynaptic reflexes and decreasing nerve transmission in spinal and supraspinal polysynaptic pathways. It is chemically a carbamate derivative of guaifenesin and shares no structural relationship with tricyclic antidepressants or benzodiazepines, which gives it a distinct side-effect profile compared to cyclobenzaprine or diazepam. The drug does not directly relax tense skeletal muscles in humans at therapeutic doses.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly and almost completely absorbed from GI tract (AHFS); Tmax ~1–2 h (oral); onset of action ~30 min; systemic bioavailability not formally determined in humans (subject to first-pass hepatic metabolism) | Food does not significantly affect absorption; fast onset supports use for acute pain episodes; high hepatic extraction may explain lower-than-expected systemic levels relative to dose |
| Distribution | Vd ~0.48 L/kg; protein binding 46–50% (healthy), 41–43% (elderly), 40–45% (hepatic impairment) | Moderate distribution volume; slightly decreased protein binding in elderly and hepatic impairment increases free drug fraction |
| Metabolism | Hepatic via dealkylation to hydroxyphenoxy metabolite and hydroxylation; followed by glucuronide and sulfate conjugation | Hepatic clearance reduced ~70% in cirrhosis (half-life ~3.4 h vs ~1.1 h); no specific CYP enzyme predominance identified |
| Elimination | t1/2 1–2 h (healthy), 1.5 h (elderly), 3.4 h (cirrhosis); clearance 0.20–0.80 L/h/kg; primarily renal as metabolites | Short half-life requires QID dosing; renal clearance reduced ~40% in dialysis patients (half-life unchanged); not appreciably dialyzable |
Side Effects
Methocarbamol was approved in 1957 before modern clinical trial adverse-event reporting standards. The FDA-approved label lists adverse reactions without specific incidence percentages. Frequency estimates below are derived from post-marketing surveillance, published case series, comparative trials, and product labelling frequency descriptors. Where exact percentages are unavailable, frequency categories from the Council for International Organizations of Medical Sciences (CIOMS) scale are used.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Drowsiness / sedation | ~10–25% (estimated from surveillance) | Most prevalent adverse effect per clinical experience (StatPearls); dose-related; less sedating than cyclobenzaprine in comparative analyses |
| Dizziness / lightheadedness | ~10–15% (estimated) | Second most reported neurological effect after drowsiness; contributes to fall risk especially in elderly |
| Headache | ~10–15% (most commonly reported per AHFS/Drugs.com) | Listed as the most commonly reported adverse reaction in some databases; may be under-recognised clinically due to overlap with the underlying musculoskeletal condition |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea / vomiting | ~3–9% (early case series ~9%) | Reported in 9 of 100 patients as a “minor” adverse effect in Forsyth 1958 case series; take with food if symptomatic |
| Blurred vision | ~1–5% | CNS-mediated; diplopia and nystagmus also reported; caution with driving |
| Metallic taste | ~1–5% | Transient; more noticeable with higher doses; not clinically significant |
| Flushing | ~1–3% | More common with IV administration; may be related to rate of injection |
| Urine discolouration | Common (not precisely quantified) | Brown, black, blue, or green discolouration; benign and clinically insignificant; important to counsel patients to prevent alarm |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylaxis / angioedema | Very rare | Minutes to hours after dose; can occur on first exposure or re-exposure | Immediate discontinuation; epinephrine, airway management, and supportive care; never re-challenge |
| Seizures (including grand mal) | Rare | Primarily reported with IV administration in patients with seizure disorders | Discontinue immediately; benzodiazepines for acute seizure; neurology consultation; avoid IV route in epilepsy |
| Syncope / severe hypotension | Rare | Minutes after IV administration; may also occur with oral dosing | Supine positioning, IV fluids; monitor vital signs; some cases required epinephrine or injectable steroids per PI |
| Cholestatic jaundice | Very rare (case reports) | Days to weeks after initiation | Discontinue; monitor liver function tests; hepatology referral; however, LiverTox notes methocarbamol has not been conclusively linked to liver injury |
| Leukopenia | Very rare | Variable | Check CBC; discontinue if significant neutropenia; haematology consultation |
While methocarbamol causes less sedation than cyclobenzaprine, drowsiness remains the most common adverse effect. The risk increases substantially when combined with alcohol, opioids, benzodiazepines, or other CNS depressants. Counsel all patients about impaired driving ability and the interaction with alcohol. For elderly patients, consider the AGS Beers Criteria recommendation to generally avoid skeletal muscle relaxants due to sedation-related injury risk.
Drug Interactions
Methocarbamol does not have a well-characterised CYP-mediated metabolic profile, and its primary interactions are pharmacodynamic rather than pharmacokinetic. The drug is a CNS depressant, and its most clinically significant interactions involve additive sedation with other CNS-active agents. The FDA PI specifically warns about combined effects with alcohol and other CNS depressants.
Monitoring
-
Symptom Response
At 48–72 h, then weekly
Routine Assess pain relief, muscle spasm resolution, and functional improvement at 48–72 hours (end of loading phase). Step down dosage if improving. Discontinue if no benefit; methocarbamol is intended for short-term use only. -
CNS Effects
Each visit
Routine Monitor for drowsiness, dizziness, confusion, and ataxia. Assess ability to drive and operate machinery safely. Particularly important in elderly patients and those on concomitant CNS depressants. -
Renal Function
Before IV/IM use
Trigger-based Check serum creatinine and eGFR before administering the injectable formulation. The polyethylene glycol 300 vehicle is contraindicated in renal pathology. For oral use, clearance is reduced ~40% in renal impairment; use cautiously. -
Hepatic Function
Baseline if risk factors
Trigger-based Total clearance reduced ~70% in cirrhosis. Consider LFTs at baseline in patients with known liver disease or heavy alcohol use. Monitor for signs of cholestatic jaundice (dark urine, pruritus, right upper quadrant pain). -
IV Administration
During and after injection
Routine Monitor blood pressure and heart rate during IV infusion (rate must not exceed 3 mL/min). Watch for syncope, bradycardia, hypotension, and thrombophlebitis. Patient should remain recumbent for 10–15 minutes after injection.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to methocarbamol or any component of the formulation
- Injectable formulation in renal impairment — the polyethylene glycol 300 vehicle can worsen pre-existing acidosis and urea retention
Relative Contraindications (Specialist Input Recommended)
- Myasthenia gravis — methocarbamol may inhibit the effect of pyridostigmine and other anticholinesterase agents; use only if the clinical benefit clearly outweighs the risk of worsening neuromuscular weakness
- Pregnancy — Pregnancy Category C; reports of fetal and congenital abnormalities following in-utero exposure; avoid unless benefits clearly outweigh risks, especially during early pregnancy
- Seizure disorders (IV administration) — IV methocarbamol has been reported to precipitate seizures in patients with epilepsy; oral route preferred in these patients
Use with Caution
- Elderly patients — AGS Beers Criteria lists skeletal muscle relaxants as potentially inappropriate; increased risk of sedation, falls, and fractures
- Hepatic impairment — clearance reduced ~70% in cirrhosis; half-life triples; use lowest effective dose and monitor closely
- Renal impairment (oral formulation) — clearance reduced ~40%; no formal dose adjustment but exercise caution
- Concurrent CNS depressants — additive sedation with alcohol, opioids, benzodiazepines, and other sedating agents
- Activities requiring mental alertness — impairs ability to operate machinery or drive a motor vehicle
Concurrent use of methocarbamol with opioid analgesics may result in profound sedation, respiratory depression, coma, and death. This combination should be reserved for patients in whom alternative treatment options are inadequate. When co-prescribed, use the lowest effective doses and minimum treatment durations, and monitor closely for signs of respiratory depression and excessive sedation. This warning aligns with the broader FDA class-wide advisory regarding skeletal muscle relaxants combined with opioids.
Patient Counselling
Purpose of Therapy
Methocarbamol is a muscle relaxant used together with rest, physical therapy, and pain medication to relieve discomfort from acute muscle spasm associated with sprains, strains, or other musculoskeletal injuries. It works by calming overactive nerve signals in the brain and spinal cord rather than acting directly on the muscles. It is intended for short-term use during the acute phase of injury.
How to Take
Take methocarbamol tablets with or without food. Swallow whole with a full glass of water. Your prescriber may start you on a higher dose for the first 2–3 days and then reduce it. Follow the prescribed schedule carefully. If you miss a dose, take it as soon as you remember, but do not double up if it is nearly time for the next dose.
Sources
- Robaxin / Robaxin-750 (methocarbamol tablets, USP). Full Prescribing Information. Schwarz Pharma, Inc. / Endo Pharmaceuticals. NDA 11-011. FDA Label Primary source for oral formulation dosing, PK parameters (t1/2, clearance, protein binding), adverse reactions, and contraindications.
- Robaxin Injectable (methocarbamol injection, USP). Full Prescribing Information. West-Ward Pharmaceuticals. Revised October 2017. Drugs.com Source for injectable dosing (IV/IM), tetanus management protocol, IV rate restrictions, and polyethylene glycol contraindication in renal impairment.
- Friedman BW, Cisewski D, Irizarry E, et al. A randomized, double-blind, placebo-controlled trial of naproxen with or without orphenadrine or methocarbamol for acute low back pain. Ann Emerg Med. 2018;71(3):348-356.e5. doi:10.1016/j.annemergmed.2017.09.031 Key RCT finding that adding methocarbamol to naproxen did not improve outcomes at 1 week for acute low back pain; informs evidence-based prescribing.
- Forsyth EL. Methocarbamol (Robaxin) in the management of orthopedic conditions: a report of one hundred cases. Can Med Assoc J. 1958;78(12):911-914. Early case series (n=100) demonstrating 94% moderate-to-pronounced relief with only 9% minor adverse effects; historical source for tolerability data.
- O’Doherty DS, Shields CD. Methocarbamol: new agent in treatment of neurological and neuromuscular diseases. JAMA. 1958;167(2):160-163. doi:10.1001/jama.1958.02990190016004 Foundational study establishing methocarbamol’s efficacy for muscle spasms in patients with pyramidal spine lesions.
- Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514-530. doi:10.7326/M16-2367 ACP guideline recommending skeletal muscle relaxants (including methocarbamol) as a second-line option for acute low back pain.
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 Lists skeletal muscle relaxants (including methocarbamol) as potentially inappropriate in older adults due to sedation, anticholinergic effects, and fracture risk.
- Bruce RB, Turnbull LB, Newman JH. Metabolism of methocarbamol in the rat, dog, and human. J Med Chem. 1971;14(6):573-575. doi:10.1021/jm00288a030 Identified methocarbamol metabolites (dealkylated and hydroxylated compounds) and confirmed urinary excretion pathway across species.
- Campbell AD, Coles FK, Eubank LL, Huf EG. Distribution and metabolism of methocarbamol. J Pharmacol Exp Ther. 1961;131:18-25. Early pharmacological study characterising tissue distribution and metabolic pathways of methocarbamol in animal models.
- Forist AA, Judy RW. Comparative pharmacokinetics of chlorphenesin carbamate and methocarbamol in man. J Pharm Sci. 1971;60(11):1686-1688. doi:10.1002/jps.2600601121 Key human PK study establishing Vd of 0.48 L/kg, t1/2 of 1.20 h, and Tmax of ~1.4 h for methocarbamol after a single 2 g oral dose.
- Spence MM, Shin PJ, Lee EA, et al. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother. 2013;47(7-8):993-998. doi:10.1345/aph.1R735 Comparative study demonstrating methocarbamol was less sedating than cyclobenzaprine but had similarly increased injury risk in older adults.
- Khan I, Bhatt H. Methocarbamol. In: StatPearls. Treasure Island (FL): StatPearls Publishing; Updated September 2024. NCBI Bookshelf Comprehensive clinical review covering pharmacology, dosing, PK parameters, pregnancy considerations, and evidence for clinical efficacy.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Methocarbamol. NCBI Bookshelf Notes that methocarbamol has not been conclusively linked to clinically significant liver or kidney injury despite jaundice listed in FDA PI.